Circassia Pharmaceuticals plc ('Circassia') announces that at its Annual General Meeting held today all resolutions set out in the notice of Annual General Meeting dated 28 April 2017 were passed. A poll was conducted on each resolution proposed at the Meeting and the number of votes cast for and against each of the resolutions, and the number of votes withheld, were as follows:
Resolution
For
%
Against
%
Withheld*
1
To receive the Annual report and accounts
281,848,844
100.00
0
0.00
0
2
To approve the Annual report on remuneration
280,821,008
99.99
29,476
0.01
998,360
3
To re-elect Francesco Granata
281,780,954
99.98
67,890
0.02
0
4
To re-elect Steve Harris
281,848,844
100.00
0
0.00
0
5
To re-elect Julien Cotta
281,848,844
100.00
0
0.00
0
6
To re-elect Rod Hafner
281,846,718
100.00
2,126
0.00
0
7
To re-elect Russell Cummings
280,829,498
99.64
1,019,346
0.36
0
8
To re-elect Jean-Jacques Garaud
281,799,847
99.98
48,997
0.02
0
9
To re-elect Marvin Samson
280,827,964
99.64
1,020,880
0.36
0
10
To re-elect Lota Zoth
281,828,951
99.99
19,893
0.01
0
11
To re-appoint PwC as auditors
280,829,465
99.64
1,019,379
0.36
0
12
To authorise the Audit Committee to determine the remuneration of the auditors
277,285,833
98.38
4,563,011
1.62
0
13
To authorise the directors to allot shares
281,841,561
100.00
7,283
0.00
0
14
To authorise the directors to dis-apply pre-emption rights**
276,261,296
98.02
5,587,548
1.98
0
15
To authorise the calling of general meetings (other than an AGM) on not less than 14 clear days' notice**
281,245,950
99.79
602,894
0.21
0
As explained in the notice of Annual General Meeting dated 28 April 2017, Circassia further announces the result of the vote of independent shareholders in respect of resolutions 8, 9, and 10.
Resolution
For
%
Against
%
Withheld*
8
To re-elect Jean-Jacques Garaud
181,716,113
99.97
48,997
0.03
0
9
To re-elect Marvin Samson
180,744,230
99.44
1,020,880
0.56
0
10
To re-elect Lota Zoth
181,745,217
99.99
19,893
0.01
0
*A vote withheld is not a vote in law and is not counted in the calculation of the votes 'For' or 'Against' a resolution.
**Special resolution.
In accordance with LR 9.6.2, a copy of the resolutions passed at today's Annual General Meeting will be submitted to the National Storage Mechanism and will be shortly available for inspection at www.morningstar.co.uk/uk/NSM.
For enquiries, contact: Julien Cotta, Company Secretary +44 (0)1865 405560.
A copy of this announcement has been posted on the company's website, www.circassia.com.
Circassia Pharmaceuticals plc published this content on 26 May 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 26 May 2017 11:16:17 UTC.
Original documenthttp://otp.investis.com/clients/uk/circassia/rns/regulatory-story.aspx?cid=797&newsid=877214
Public permalinkhttp://www.publicnow.com/view/D8A40B71E1A0EE71C0ED24C768F92FBBFE27F42E
NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company's product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
NIOX GROUP PLC 
